|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on July 5, 2002; DOI 10.1182/blood-2002-01-0312.
IMMUNOBIOLOGY
From the Institut National de la Santé et
de la Recherche Médicale (INSERM) U255, Centre de
Recherches Biomédicales des Cordeliers, and Unité de
Génétique Mycobactérienne, Institut Pasteur, Paris,
France; INSERM U346, Hôpital Edouard Herriot, and INSERM U453,
Centre Léon Bérard, Lyon, France; and Liver Unit
Laboratories, Queen Elizabeth Hospital, Birmingham, Great
Britain.
Immature dendritic cells (DCs) reside in interstitial tissues
(int-DC) or in the epidermis, where they capture antigen and, thereafter, mature and migrate to draining lymph nodes (LNs), where
they present processed antigen to T cells. We have identified int-DCs
that express both TRANCE (tumor necrosis factor-related activation-induced cytokine) and RANK (receptor activator of NF- The decision between cell survival and death is
fundamental to the shaping of the immune system. Dendritic cells (DCs)
reside in peripheral tissues in an immature state for optimal antigen uptake and, in response to inflammatory signals, mature and migrate to
secondary lymphoid organs to activate antigen-specific T
cells.1 Early studies using continuous
[3H]thymidine labeling and skin or bone marrow
transplantation found that the turnover rate of peripheral DCs
was relatively slow compared with that of DCs in lymph nodes
(LNs).2 In particular, it was found that Langerhans DCs
(L-DCs) of the skin epithelium display a remarkably long half-life, as
L-DCs could still be detected in the skin epithelium 9 weeks after skin
transplantation.3 More recently, using BrdU incorporation
combined with the ability to isolate specific DC subsets, the turnover
kinetics of mouse DC subpopulations was measured, and it was found that
the half-lives of both L-DCs and dermal interstitial DC (int-DCs) were
long (about 14 days and 8 days, respectively)4 (K. Shortman, written personal communication, March 2002). On the
other hand, mature DCs in secondary lymphoid organs have a much reduced
lifespan,4,5 making it difficult to detect DCs in the
T-cell zone only 2 days after immunization.6 A long
half-life may be beneficial for immature DCs to fulfill their function
as sentinels in peripheral tissues, but a fast turnover of mature DCs
ensures the continuous exposure of the adaptive immune system to
novel antigens.
TRANCE (tumor necrosis factor-related activation-induced cytokine)
(also called RANKL/ODF/OPGL)7-10 represents a recently identified member of the tumor necrosis factor (TNF)- In view of the finding that TRANCE is involved in the survival of
mature DCs, we investigated the role of TRANCE and RANK in the survival
of immature DCs. We show that CD14+ int-DCs in human dermis
and liver coexpress TRANCE and RANK. We have generated
macrophage-related cells from CD34+ human progenitors using
macrophage colony-stimulating factor M-CSF and found that these
cells carry markers characteristic of dermal int-DCs20-22
and express TRANCE and RANK. These cells, which we refer to as
CD34+-derived int-DCs, are long-lived in culture, but
addition of soluble RANK leads to significant reduction of cell
viability and Bcl-2 expression, suggesting that constitutive
TRANCE-RANK interaction is associated with CD34+-derived
int-DC longevity. Conversely, CD1a+ DCs express RANK but
lack TRANCE and are short-lived. However, they can be rescued from cell
death either by recombinant soluble TRANCE or by
CD34+-derived int-DCs. CD34+-derived int-DCs
mature in response to lipopolysaccharide (LPS)/CD40L and, once
mature, migrate in a CCL21/CCL19-chemotactic gradient and induce
proliferation of naive CD4+ T cells. Upon maturation they
lose TRANCE but retain RANK expression. These results underpin the
importance of TRANCE and RANK for immature DC homeostasis and provide
further evidence for the important function of these TNF family members
in the immune system.
Immunohistochemistry
Cell culture
Phenotypic analysis Expression of specific markers was determined by flow cytometry on a FACSCalibur (Becton Dickinson) and the following Ab: CD14-FITC, CD4-FITC, HLA DR-FITC (Becton Dickinson), CD1a-PE (Immunotech/Coulter), M-CSF receptor (Zymed), FXIIIa (Calbiochem), TRANCE (R&D Systems), RANK (R&D Systems and Santa Cruz Biotechnology, Santa Cruz, CA), CD40-PE, CD40L-PE, CD80-PE, CD83-PE, CD11b-FITC, CD11c-PE, CD21-FITC, CD35-FITC, CD16-FITC, CD64-FITC (Immunotech/Coulter), CD86-FITC, and CD32-FITC (Pharmingen). Secondary Ab were all FITC-F(ab')2 goat Ab from Jackson ImmunoResearch (West Grove, PA). The analyses were done using the CellQuest software (Beckton-Dickinson). 15 × 106 COBS cells were transfected by electoporation with a plasmid coding for the flag-tagged full-length human TRANCE cDNA (kindly provided by Y. Choi) under the control of a viral promotor. Cells were detached 24 hours after transfection, fixed in 4% PBS-buffered paraformaldehyde, and incubated with isotype control Ab, anti-Flag Ab (Stratagene, La Jolla, CA), and anti-TRANCE Ab (R&D Systems).Reverse transcriptase-polymerase chain reaction and Western blot analyses Total RNA was extracted from CD34+-derived int-DCs, unsorted CD34+-derived DCs (with or without maturation by CD40L), and total peripheral blood T cells, activated by anti-CD3/CD28 mAb. RNA was reverse-transcribed using standard procedures and subject to polymerase chain reaction (PCR) with the following primer pairs: TRANCE: 5'-AAATCCCAAGTTCTCATACCC and 5'-TCTCATAAGGTCAACCCGTAA, RANK: 5'-GTACACACACGGCAAAC and 5'-TGCTCTGTGTCCCCGTGAAGC, OPG 5'-CGCAAAAGTGTGGAATAGATGT and 5'-TGAGTGACAGTTTTGGGAAAGTG. -actin primers were from Clontech (Palo Alto, CA). Cells were lysed
in radioimmunoprecipitation assay (RIPA) buffer (10 mM
Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA
[ethylenediaminetetraacetic acid], 1% Triton X-100, 0.5% Na-deoxyycholate, 0.1% sodium dodecyl sulfate [SDS],
aprotinin, phenylmethylsulfonyl fluoride [PMSF], leupeptin).
Cleared cell lysates were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
blotted onto nylon membrane. As control, 10 ng RANK-Fc (R&D Systems)
and 50 ng soluble TRANCE (Peprotech, Rocky Hill, NJ) were loaded. Nylon
membranes were saturated in Tris-buffered 5% milk and incubated with
anti-RANK (R&D Systems) and anti-TRANCE (C-20, Santa Cruz
Biotechnologies) Ab. Western blots were developed using the ECL-kit
(Amersham-Pharmacia, Little Chalfont, United Kingdom) or NBC/BCIP
coloration (Pierce, Rockford, IL).
Cell survival studies CD34+-derived int-DCs were cultured at 105 cells/mL in the presence of either 100 ng/mL human IgG1 (Sigma) or human RANK-Fc (R&D Systems). IgG1 and RANK-Fc were renewed every 3 days. After 12 days, CD34+-derived int-DC viability was determined by trypan blue exclusion of dead cells, and cells were stained for intracellular Bcl-2 using fluorescein isothiocyanate (FITC)-conjugated Ab (DAKO). 2 × 105 L-DCs were washed and placed into a 12-well plate in cytokine-free medium under the following conditions: L-DCs alone, L-DCs in the presence of 50 ng/mL recombinant human TRANCE (Peprotech), in the presence of 105 CD34+-derived int-DCs with 500 ng/mL IgG1, or 500 ng/mL RANK-Fc. After 2 days, cell viability was determined by trypan blue exclusion of dead cells, and cells were double-stained with anti-Bcl-2-FITC (DAKO) and anti-CD14-PE (Becton Dickinson) or anti-CD1a-PE (Coulter). Student unpaired t test was used to analyze statistical significance.Phagocytosis assay A recombinant strain of Mycobacterium bovis bacillus Calmette-Guérin (BCG) (Myc409) was used expressing a mutated form of the green fluorescent protein (GFP) from Aequoria victoria. The gfp gene was cloned under the control of the strong mycobacterial promoter pBlaF* and the expression cassette inserted into the BCG chromosome by means of an integrative vector derived from the mycobacteriophage Ms6. On day 1 of infection, CD34+-derived int-DCs were infected in complete medium lacking antibiotics with Myc409 at a multiplicity of infection (MOI) of either 1 or 10 bacteria for 1 int-DC. Cells were washed 4 hours later and complete medium without antibiotics added. Cells were harvested 20 hours later, and phagocytosed Myc409 bacilli were detected by flow cytometry.Chemotactic cell migration Chemotactic cell migration was assessed using a chemotaxis Boyden microchamber with a standard 5-µm pore polycarbonate filter (Neuroprobe, Gaithersburg, MD).26 Migration of 105 unstimulated, LPS-, and LPS/CD40L-treated CD34+-derived int-DCs was analyzed in response to 100 ng/mL CCL20, 500 ng/mL CCL19, and 100 ng/mL CCL21 (R&D Systems) after incubation at 37°C for 1 hour and 30 minutes.Allogeneic mixed lymphocyte reaction assay Unstimulated, LPS-, and LPS/CD40L-stimulated CD34+-derived int-DCs, as well as CD14+ precursor cell-derived CD1a+ DCs, were treated with mitomycin C (Sigma). Graded doses of stimulator cells were seeded with 2 × 104 T cells in microtest culture plates in RPMI medium containing 10% FCS. T-cell proliferation was measured after 5 days of culture following an overnight incubation with 1 µCi (0.037 MBq) of [3H]thymidine.
Identification of TRANCE+RANK+ cells in human skin We analyzed the distribution of DC survival factors in peripheral tissues and observed cells in the dermis of human skin that expressed both TRANCE and RANK (Figure 1A, indicated by arrows). They were in the vicinity of cells expressing only RANK, which could be vascular endothelial cells or CD1a+ L-DCs.8 Further double-labeling analyses revealed that TRANCE+ cells also expressed Factor (F) XIIIa (Figure 1B), CD14 (Figure 1C), and M-CSF receptor (Figure 1D), but lacked CD1a (Figure 1E). Close to blood vessels (arrows, Figure 1B), TRANCE+ cells lacked FXIIIa, suggesting that they acquire in the stromal environment this marker that is characteristic of the dermal monocyte/macrophage subset.20,27 CD1a+ cells in the dermis (Figure 1E, between arrowheads) were often found in the vicinity of TRANCE+ cells but lacked TRANCE expression. Taken together, these findings suggest that TRANCE and RANK are expressed by a dermal monocyte/macrophage subset in healthy human skin.
Int-DCs express TRANCE and RANK To verify the immunohistochemical findings, CD14+ cells were purified from human skin and analyzed for TRANCE and RANK expression by flow cytometry. As shown in Figure 2A, all CD14+ cells expressed RANK, and a subset also expressed TRANCE. Next, we purified int-DCs from liver, an organ that, compared with heart or kidney, is relatively rich in int-DCs,28 and tested the cells for TRANCE and RANK expression. As shown in Figure 2B, liver DCs expressed RANK and also TRANCE, albeit more weakly than RANK. These data suggest that CD14+ int-DCs express both TRANCE and RANK. The low TRANCE expression could be related to the spontaneous maturation of ex vivo-purified DCs29,30 combined with the fact that TRANCE is down-regulated on mature DCs (see below).
To study the role of TRANCE and RANK on int-DCs we sought to
generate these cells in vitro. However, monocyte-derived DCs grown in
the presence of GM-CSF and IL-4 carry the CD1a antigen but not CD14 or
TRANCE (Sallusto and Lanzavecchia31 and data not shown).
We therefore generated macrophage-related cells from CD34+
progenitors using a previously described method25 (Figure
2C). Human CD34+ progenitors were grown in SCF, GM-CSF, and
TNF- To confirm TRANCE and RANK expression, we performed reverse
transcriptase (RT)-PCR analyses on cDNA prepared from
CD34+-derived int-DCs as well as from CD40L-matured DCs and
activated T cells known to express RANK and TRANCE,
respectively.7,8 As shown in Figure
3A, CD34+-derived int-DCs
transcribe TRANCE and RANK but not OPG, which acts as a decoy receptor
for TRANCE.11 We also verified the specificity of the Ab
directed against TRANCE, used in the immunohistochemical and flow
cytometry studies, by transfecting COBS cells with Flag-tagged human
TRANCE cDNA.7 As shown in Figure 3B, 28% of transfected cells are recognized by the anti-Flag Ab and 20% are recognized by the
anti-TRANCE Ab. Finally, we detected TRANCE and RANK expression by
Western blot analysis (Figure 3C-D). Full-length RANK and recombinant soluble RANK-Fc migrated with an apparent molecular weight of about 90 kDa and about 70 kDa, respectively, and full-length
TRANCE and recombinant soluble TRANCE with an apparent molecular weight of about 42 kDa and about 20 kDa, respectively (arrowheads). Taken together, CD34-derived int-DCs resemble DCs of interstitial tissues on
the basis of expression of common markers including TRANCE and RANK.
CD34+-derived int-DCs survival is mediated by TRANCE-RANK interaction We observed that CD34+-derived int-DCs remained immature and viable in culture for more than 2 weeks without addition of cytokines. In light of the role of TRANCE in mature DC survival,18 we wondered whether this longevity was the consequence of constitutive RANK signaling caused by TRANCE and RANK coexpression. To address this question, CD34+-derived int-DCs were cultured for 12 days in the presence of control IgG1 or soluble RANK-Fc fusion protein in order to interrupt TRANCE interaction with membrane RANK. After this prolonged culture, 72% of IgG1-treated CD34+-derived int-DCs were still alive, whereas in the RANK-Fc-treated samples, only 33% remained viable (Figure 4A). Reduction of cell viability by addition of RANK-Fc is reflected in Bcl-2 levels, as in the presence of soluble RANK-Fc, 2-fold fewer CD34+-derived int-DCs expressed Bcl-2 (Figure 4B). Identical results were obtained with soluble RANK lacking the cytoplasmic domain (data not shown). These results suggest that CD34+-derived int-DCs are long-lived due to Bcl-2 expression sustained by constitutive TRANCE-RANK ligation.
CD34+-derived int-DCs can rescue L-DCs from cell death Besides TRANCE+RANK+ int-DCs, interstitial dermal tissue also contained cells that expressed RANK but lacked TRANCE (Figure 1A). These might be L-DCs migrating from the dermal vasculature to the epidermis or leaving the epidermis to home to draining LN. Immature CD1a+ DCs (L-DCs) derived from CD34+ progenitors in the presence of GM-CSF (Figure 5A) expressed RANK but lacked TRANCE (Figure 5B). Placed into fresh culture medium in the absence of cytokines, a great number of L-DCs underwent cell death, in contrast to CD34+-derived int-DCs (Figure 5C). Addition of soluble recombinant TRANCE partially rescued L-DCs from cell death. To test whether CD34+-derived int-DCs can likewise rescue L-DCs from cell death, L-DCs were cocultured with CD34+-derived int-DCs (ratio: 2 L-DCs to 1 CD34+-derived int-DC) in the presence of control IgG1 and RANK-Fc. Total cell viability of these cocultures was 79% in the presence of control IgG1, compared with only 41% in the presence of RANK-Fc. This suggests that CD34+-derived int-DCs can support L-DC cell viability by intercellular TRANCE-RANK engagement. To ascertain that L-DCs were rescued from cell death, we analyzed Bcl-2 expression in the cocultures. In the presence of IgG1, 56% of all cells express CD1a and Bcl-2, however, in the presence of RANK-Fc, only 20% of all cells express CD1a and Bcl-2. Identical results were obtained with soluble RANK lacking the cytoplasmic domain (data not shown). Separation of L-DCs and int-DCs by a transwell membrane did not rescue L-DCs from cell death, indicating that cell-cell contact is required and that TRANCE is not shed by int-DCs (data not shown). These results suggest that immature DCs that express RANK but lack TRANCE are short-lived, but their viability can be prolonged by soluble TRANCE or by coculture with TRANCE+ CD34+-derived int-DCs.
CD34+-derived int-DCs capture antigen CD34+-derived int-DCs are generated in the presence of M-CSF and express CD14 but are distinct from typical macrophages by the absence of CD16 (Figure 2D) and complete lack of adherence to plastic cell surfaces (Figure 6A). Giemsa coloration or staining for HLA DR revealed a veiled cell morphology, an extensive cytoplasm with numerous vacuoles, suggesting active endocytosis. Indeed, after the addition of heat-killed yeast S cerevisiae, CD34+-derived int-DCs were filled with yeast bodies (Figure 6A). To better assess antigen capture, Myc409, a live strain of recombinant Mycobacterium bovis BCG expressing GFP was added to CD34+-derived int-DCs for 4 hours and uptake of Myc409 was measured by flow cytometry. As shown in Figure 6B, at a multiplicity of infection (MOI) of only one mycobacterium per cell, 85% of CD34+-derived int-DCs captured Myc409 with a mean fluorescence intensity (MFI) of 962 units. Increasing the dose to an MOI of 10 resulted in virtually all cells capturing Myc409 with an MFI that has increased 6-fold. This shows that CD34+-derived int-DCs are capable of rapidly capturing a great number of microorganisms.
Maturation into APC in response to LPS/CD40L Next, we wondered whether CD34+-derived int-DCs would mature into professional APCs upon encounter with DC maturation signals. Stimulation with endotoxin resulted in cell aggregation (Figure 7A), increased expression of CD80 and CD40, but diminished CD11b and CD14 expression (Figure 7B). A small proportion of cells expressed CD83. The up-regulation of CD40 prompted us to subsequently provide an anti-CD40 (Figure 7A) or a CD40L signal (Figure 7B). This led to (1) formation of large free-floating cell aggregates with distinct dendritic cell extensions (Figure 7A), (2) a rise in the levels of HLA DR with acquisition of CD83, and (3) increased expression of CD80 and CD86. LPS/CD40L-stimulated cells lost TRANCE expression but continued to express RANK (Figure 7B).
We next addressed the question of whether untreated or stimulated
CD34+-derived int-DCs would migrate in response to the
chemokines CCL20 (MIP3
TRANCE and RANK are markers for interstitial DC In this report, we have shown that an interstitial cell population in the human skin coexpresses TRANCE and RANK. We have characterized these cells further and observed that they carry markers characteristic of dermal int-DCs, that is, CD14, Factor XIIIa, and MCSF-R.20-22 In addition, CD14+ DCs purified from human skin and liver also expressed TRANCE and RANK. Cells that express these markers could be generated from CD34+ progenitors by growth in GM-CSF, TNF- , and SCF, followed by culturing the CD14+ subset in M-CSF. These cells capture
antigen efficiently and mature into professional APCs in response
to LPS/CD40L.
Given the plasticity of the myelomonocytic cell lineage, the phenotypic distinction between macrophages and immature DCs in the healthy interstitial environment is difficult. Human macrophages and immature DCs share a great number of antigenic markers, such as Factor XIIIa and CD11c. However, in contrast to macrophages, which are terminally differentiated, immature DCs can further differentiate into professional APCs capable of activating naive T cells. The cells we have generated in vitro share antigenic markers with macrophages, yet because they are (1) nonadherent, (2) display a veiled cell morphology, and (3) can further differentiate into mature DCs capable of activating naive T cells, it is appropriate to consider them to be immature DCs rather than macrophages. Our observations concur with those of Lu and colleagues, who showed that cells can been grown from liver stem cells that likewise resemble macrophages and immature DCs and that can mature into professional APCs.32 Also, the M-CSF-dependent subcapsular sinus macrophages that express weakly CD11c but strongly sialoadhesin, a marker shared with macrophages, can differentiate into professional APCs.33 Finally, it has been found that a subpopulation of monocytes cultured in M-CSF has the capacity to undergo differentiation into mature DCs.34,35 These observations suggest the existence of an uncommitted myeloid cell within interstitial tissues, which has been termed by some investigators "precursor DC"28 or "dendrophage."36 It is important to underline the diversity of interstitial tissues,
which stems from heterogeneous cell composition and from the influence
of neighboring environments. For instance, dermal int-DCs are exposed
on one hand to GM-CSF secreted by neighboring keratinocytes, and on the
other hand to M-CSF and IL-6 produced by endothelial cells and
collagen-associated fibroblasts. This changing cytokine milieu is
likely to create a spaciotemporal heterogeneity in the int-DC
population. Such heterogeneity was observed by Meunier and colleagues,
who noted among major histocompatibility complex
(MHC)-II+ dermal cells a low number of
CD1a+Factor XIIIa+ DCs.37 Further
support for the dynamic nature of the int-DC population is provided by
the observation that human dermal CD14+ cells can
differentiate into bona fide L-DCs in the presence of GM-CSF and
TGF- DC viability Measurements of steady-state turnover rates for mouse dermal int-DCs and L-DCs isolated from cutaneous-draining LNs and skin showed that both peripheral DC subsets display slow renewal in the skin.4 Dermal int-DCs obtained from skin require 14 days for BrdU incorporation by 77% of the cells, and 27% of L-DCs are labeled during the same time period. In contrast, once migrated to the draining LNs, DCs showed rapid turnover, which is even faster after microbial product stimulation (K. Shortman, written personal communication, March 2002). We found that CD34+-derived int-DCs were long-lived in culture and insensitive to cytokine-free medium for 2 days. In view of the role of TRANCE and RANK in cell survival,14,18 we hypothesized that the longevity of CD34+-derived int-DCs could be due to constitutive engagement of RANK by TRANCE. Indeed, addition of soluble RANK led to significant loss of Bcl-2 expression and cell death. By coexpressing TRANCE and RANK, CD34+-derived int-DCs appear to maintain cell viability in an autocrine survival loop. As our data suggest that TRANCE is not shed from the membrane, the simplest scenario is that TRANCE and RANK are constitutively ligated on the same cell. Yet we cannot formally exclude the possibility that cell-to-cell contact between int-DCs is required to maintain cell viability, but this is likely to occur given that int-DCs are frequently clustered around vessels and are considered highly mobile. On the other hand, mature CD34+-derived int-DCs down-regulated TRANCE while retaining RANK, suggesting that as CD34+-derived int-DCs mature they become short-lived and increasingly dependent upon exogenous factors for survival. This finding would be in accord with the faster turnover kinetics of DCs in draining LNs. CD1a+ L-DCs expressed RANK but lacked TRANCE and died rapidly in cytokine-free medium. L-DCs could be rescued from cell death by addition of either soluble recombinant TRANCE or TRANCE expressed by CD34+-derived int-DCs. As our data suggest that TRANCE is not shed, cell contact between int-DCs and L-DCs would be necessary to support cell viability. This would confine int-DC to L-DC interaction to the interstitial space when L-DCs migrate from the dermis toward the epithelium or from the epidermis toward draining LNs. On the other hand, in view of the finding that DCs can send dendrites across an intact epithelial barrier,40 it may not be too surprising if int-DCs and L-DCs could interact by an analogous mechanism. One can also anticipate that epithelial cells may contribute to L-DC longevity, and it may be important to address these issues in further experiments. In support of the idea that TRANCE+ int-DC influences L-DC viability and, thus, cell number, is the observation that osteopetrotic op/op mice, which lack dermal F4/80+ macrophages,41 show only 60% of normal L-DC numbers.42 We have observed in mice that dermal F4/80+ cells express TRANCE and RANK and that L-DCs express only RANK (C.G.F.M. and Y. Choi, data not shown, May 2001).Functional int-DC subsets CD34+-derived int-DCs were efficient antigen-capturing cells as they rapidly internalized a great number of yeast bodies and Mycobacterium bovis bacilli. In response to LPS/CD40L, CD34+-derived int-DCs matured into professional APCs displaying high levels of MHC-II and costimulatory molecules and acquiring expression of CD83. LPS/CD40L-stimulated CD34+-derived int-DCs responded to the chemoattractants CCL19 and CCL20, which would facilitate migration to draining LNs and could efficiently stimulate proliferation of naive CD4+ T cells. This suggests that int-DCs play an important role in the defense against invading pathogens and in the link between the innate arm and the adaptive immune system. In healthy human dermis, CD14+ cells outnumber CD1a+ cells, but it is likely that in response to infection or inflammation conditions (when cytokines such as GM-CSF and IL4 or interferon [IFN] are induced), DC precursors
will preferentially differentiate into CD1a+ DCs. We
hypothesize that, although both DC subsets when matureare equally
potent T-cell stimulators, they may direct differently the adaptive
immune response. For instance, it has been shown that while
CD1a+ DCs direct T-cell polarization toward the Th1 type,
CD1a DCs generate Th0 effector T cells.43 We
are currently investigating effector T-cell polarization by
CD34+-derived int-DCs. Because CD14+ int-DCs
outnumber CD1a+ int-DCs in healthy tissue, it is plausible
that these cells are implicated in peripheral
tolerance.44,45 In this context, their longevity could
help detect and phagocytose apoptotic cells,46,47 which in
healthy tissue with low antigenic load is usually a rare event. In
support of a role of long-lived CD14+ int-DCs in tolerance
is the finding that liver DCs have been associated with long-term graft
tolerance and have been found in the T-cell zone of draining LNs up to
2 months after injection into the host.48 Also, it has
been observed in a model of cytotoxic T lymphocytes (CTLs)
induction to tumor antigens that continuous antigen presentation can be
associated with T-cell tolerization.49 The role of TRANCE
and RANK in immature DC survival could provide a molecular framework to
further address the role of DCs in tolerance and tumor or
microbial immunity.
We are grateful to C. Gardner, R. Blanque, and S. Roman-Roman (Aventis, Romainville, France) for kindly providing recombinant RANK-Fc and for helpful discussions. The plasmid-encoding human TRANCE cDNA was kindly provided by Y. Choi (University of Pennsylvania School of Medicine, Philadelphia, PA). We thank the staff of the Bourg-La-Reine maternity ward for providing umbilical cord blood. Special thanks to Z. Maciorowski (Institut Curie, Paris, France) for cell sorting. We also thank J. Davoust (Institut Gustave Roussy, Villejuif, France) and Y. Choi for helpful discussions and reading of the manuscript.
Submitted February 5, 2002; accepted June 18, 2002.
Prepublished online as Blood First Edition Paper, July 5, 2002; DOI 10.1182/blood-2002-01-0312.
Supported by INSERM, Université Pierre and Marie Curie, Institut Curie, Hoechst-Marion-Roussel, a grant from the Medical Research Council, and the Roche Organ Transplantation and Research Foundation. I.C. is a recipient of a postdoctoral fellowship from ARC (Association pour la Recherche contre le Cancer), and M.-C.D.-N. is a recipient of a postdoctoral fellowship from the Hoechst-Marion-Roussel Research Foundation.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Chris G. F. Mueller, INSERM U255, Centre de Recherches Biomedicales des Cordeliers, 15 rue de l'Ecole de Medecine, Paris 75270, cedex 6; e-mail: chmuller{at}infobiogen.fr.
1. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811[CrossRef][Medline] [Order article via Infotrieve]. 2. Fossum S. Dendritic leukocytes: features of their in vivo physiology. Res Immunol. 1989;140:883-891[CrossRef][Medline] [Order article via Infotrieve]. 3. Chen HD, Ma CL, Yuan JT, Wang YK, Silvers WK. Occurrence of donor Langerhans cells in mouse and rat chimeras and their replacement in skin grafts. J Invest Dermatol. 1986;86:630-633[CrossRef][Medline] [Order article via Infotrieve].
4.
Ruedl C, Koebel P, Bachmann M, Hess M, Karjalainen K.
Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes.
J Immunol.
2000;165:4910-4916
5.
De Smedt T, Pajak B, Klaus GG, et al.
Antigen-specific T lymphocytes regulate lipopolysaccharide-induced apoptosis of dendritic cells in vivo.
J Immunol.
1998;161:4476-4479
6.
Ingulli E, Mondino A, Khoruts A, Jenkins MK.
In vivo detection of dendritic cell antigen presentation to CD4(+) T cells.
J Exp Med.
1997;185:2133-2141
7.
Wong BR, Rho J, Arron J, et al.
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.
J Biol Chem.
1997;272:25190-25194 8. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-179[CrossRef][Medline] [Order article via Infotrieve].
9.
Yasuda H, Shima N, Nakagawa N, et al.
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
Proc Natl Acad Sci U S A.
1998;95:3597-3602 10. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176[CrossRef][Medline] [Order article via Infotrieve]. 11. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319[CrossRef][Medline] [Order article via Infotrieve]. 12. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323[CrossRef][Medline] [Order article via Infotrieve].
13.
Dougall WC, Glaccum M, Charrier K, et al.
RANK is essential for osteoclast and lymph node development.
Genes Dev.
1999;13:2412-2424 14. Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103:41-50[CrossRef][Medline] [Order article via Infotrieve].
15.
Croucher PI, Shipman CM, Lippitt J, et al.
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
Blood.
2001;98:3534-3540 16. Shalhoub V, Elliott G, Chiu L, et al. Characterization of osteoclast precursors in human blood. Br J Haematol. 2000;111:501-512[CrossRef][Medline] [Order article via Infotrieve].
17.
Kim D, Mebius RE, MacMicking JD, et al.
Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE.
J Exp Med.
2000;192:1467-1478
18.
Wong BR, Josien R, Lee SY, et al.
TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.
J Exp Med.
1997;186:2075-2080 19. Green EA, Choi Y, Flavell RA. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity. 2002;16:183-191[CrossRef][Medline] [Order article via Infotrieve]. 20. Headington JT. The dermal dendrocyte. Adv Dermatol. 1986;1:159-171[Medline] [Order article via Infotrieve]. 21. Sontheimer RD, Matsubara T, Seelig LL Jr. A macrophage phenotype for a constitutive, class II antigen-expressing, human dermal perivascular dendritic cell. J Invest Dermatol. 1989;93:154-159[CrossRef][Medline] [Order article via Infotrieve]. 22. Cerio R, Spaull J, Jones EW. Histiocytoma cutis: a tumour of dermal dendrocytes (dermal dendrocytoma). Br J Dermatol. 1989;120:197-206[Medline] [Order article via Infotrieve]. 23. Dezutter-Dambuyant C, Cordier G, Schmitt D, Faure M, Laquoi C, Thivolet J. Quantitative evaluation of two distinct cell populations expressing HLA-DR antigens in normal human epidermis. Br J Dermatol. 1984;111:1-11[Medline] [Order article via Infotrieve].
24.
Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J.
GM-CSF and TNF-
25.
Caux C, Vanbervliet B, Massacrier C, et al.
CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF
26.
Dieu MC, Vanbervliet B, Vicari A, et al.
Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites.
J Exp Med.
1998;188:373-386 27. Cerio R, Griffiths CE, Cooper KD, Nickoloff BJ, Headington JT. Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol. 1989;121:421-431[CrossRef][Medline] [Order article via Infotrieve]. 28. Thomson AW, Lu L. Are dendritic cells the key to liver transplant tolerance? Immunol Today. 1999;20:27-32[CrossRef][Medline] [Order article via Infotrieve]. 29. Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunol. 1993;151:6535-6545[Abstract].
30.
O'Doherty U, Steinman RM, Peng M, et al.
Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium.
J Exp Med.
1993;178:1067-1078
31.
Sallusto F, Lanzavecchia A.
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
J Exp Med.
1994;179:1109-1118
32.
Lu L, Woo J, Rao AS, et al.
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen.
J Exp Med.
1994;179:1823-1834
33.
Berney C, Herren S, Power CA, Gordon S, Martinez-Pomarez L, Kosco-Vilbois MH.
A member of the dendritic cell family that enters B cell follicles and stimulates primary antibody responses identified by a mannose receptor fusion protein.
J Exp Med.
1999;190:851-860
34.
Palucka KA, Taquet N, Sanchez-Chapuis F, Gluckman JC.
Dendritic cells as the terminal stage of monocyte differentiation.
J Immunol.
1998;160:4587-4595
35.
Zou W, Borvak J, Marches F, et al.
Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12.
J Immunol.
2000;165:4388-4396 36. Nickoloff BJ, Griffiths CE. Not all spindled-shaped cells embedded in a collagenous stroma are fibroblasts: recognition of the "collagen-associated dendrophage." J Cutan Pathol. 1990;17:252-254[CrossRef][Medline] [Order article via Infotrieve]. 37. Meunier L, Gonzalez-Ramos A, Cooper KD. Heterogeneous populations of class II MHC+ cells in human dermal cell suspensions: identification of a small subset responsible for potent dermal antigen-presenting cell activity with features analogous to Langerhans cells. J Immunol. 1993;151:4067-4080[Abstract]. 38. Larregina AT, Morelli AE, Spencer LA, et al. Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol. 2001;2:1151-1158[CrossRef][Medline] [Order article via Infotrieve]. 39. Holt PG, Haining S, Nelson DJ, Sedgwick JD. Origin and steady-state turnover of class II MHC-bearing dendritic cells in the epithelium of the conducting airways. J Immunol. 1994;153:256-261[Abstract]. 40. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001;2:361-367[CrossRef][Medline] [Order article via Infotrieve]. 41. Cecchini MG, Dominguez MG, Mocci S, et al. Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse. Development. 1994;120:1357-1372[Abstract]. 42. Witmer-Pack MD, Hughes DA, Schuler G, et al. Identification of macrophages and dendritic cells in the osteopetrotic (op/op) mouse. J Cell Sci. 1993;104:1021-1029[Abstract].
43.
Chang CC, Wright A, Punnonen J.
Monocyte-derived CD1a+ and CD1a
44.
Hawiger D, Inaba K, Dorsett Y, et al.
Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo.
J Exp Med.
2001;194:769-779
45.
Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N.
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.
J Exp Med.
2001;193:233-238
46.
Steinman RM, Turley S, Mellman I, Inaba K.
The induction of tolerance by dendritic cells that have captured apoptotic cells.
J Exp Med.
2000;191:411-416
47.
Huang FP, Platt N, Wykes M, et al.
A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes.
J Exp Med.
2000;191:435-444 48. Thomson AW, Lu L, Subbotin VM, et al. In vitro propagation and homing of liver-derived dendritic cell progenitors to lymphoid tissues of allogeneic recipients: implications for the establishment and maintenance of donor cell chimerism following liver transplantation. Transplantation. 1995;59:544-551[CrossRef][Medline] [Order article via Infotrieve].
49.
den Boer AT, Diehl L, van Mierlo GJ, et al.
Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance.
J Immunol.
2001;167:2522-2528
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Kwan Tat, N. Amiable, J.-P. Pelletier, C. Boileau, D. Lajeunesse, N. Duval, and J. Martel-Pelletier Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis Rheumatology, December 1, 2009; 48(12): 1482 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Chino, K. E. Draves, and E. A. Clark Regulation of dendritic cell survival and cytokine production by osteoprotegerin J. Leukoc. Biol., October 1, 2009; 86(4): 933 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-B. O. Barbaroux, M. Beleut, C. Brisken, C. G. Mueller, and R. W. Groves Epidermal Receptor Activator of NF-{kappa}B Ligand Controls Langerhans Cells Numbers and Proliferation J. Immunol., July 15, 2008; 181(2): 1103 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lorenzo, M. Horowitz, and Y. Choi Osteoimmunology: Interactions of the Bone and Immune System Endocr. Rev., June 1, 2008; 29(4): 403 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D H Adams, B Eksteen, and S M Curbishley Immunology of the gut and liver: a love/hate relationship Gut, June 1, 2008; 57(6): 838 - 848. [Full Text] [PDF]
|
|
|
|
|
|
Q. Wang, Y. Liu, J. Wang, G. Ding, W. Zhang, G. Chen, M. Zhang, S. Zheng, and X. Cao Induction of Allospecific Tolerance by Immature Dendritic Cells Genetically Modified to Express Soluble TNF Receptor J. Immunol., August 15, 2006; 177(4): 2175 - 2185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Bechetoille, V. Andre, J. Valladeau, E. Perrier, and C. Dezutter-Dambuyant Mixed Langerhans cell and interstitial/dermal dendritic cell subsets emanating from monocytes in Th2-mediated inflammatory conditions respond differently to proinflammatory stimuli J. Leukoc. Biol., July 1, 2006; 80(1): 45 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-H. Kwan, A.-M. Helt, C. Maranon, J.-B. Barbaroux, A. Hosmalin, E. Harris, W. H. Fridman, and C. G. F. Mueller Dendritic Cell Precursors Are Permissive to Dengue Virus and Human Immunodeficiency Virus Infection J. Virol., June 15, 2005; 79(12): 7291 - 7299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tenca, A. Merlo, E. Merck, E. E. M. Bates, D. Saverino, R. Simone, D. Zarcone, G. Trinchieri, C. E. Grossi, and E. Ciccone CD85j (Leukocyte Ig-Like Receptor-1/Ig-Like Transcript 2) Inhibits Human Osteoclast-Associated Receptor-Mediated Activation of Human Dendritic Cells J. Immunol., June 1, 2005; 174(11): 6757 - 6763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Goddard, J. Youster, E. Morgan, and D. H. Adams Interleukin-10 Secretion Differentiates Dendritic Cells from Human Liver and Skin Am. J. Pathol., February 1, 2004; 164(2): 511 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chougnet Role of CD40 Ligand dysregulation in HIV-associated dysfunction of antigen-presenting cells J. Leukoc. Biol., November 1, 2003; 74(5): 702 - 709. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
B) and have generated these cells from CD34+ human progenitor
cells using macrophage colony-stimulating factor (M-CSF). These
CD34+-derived int-DCs, which are related to
macrophages, are long-lived, but addition of soluble RANK leads to
significant reduction of cell viability and Bcl-2 expression. This
suggests that constitutive TRANCE-RANK interaction is responsible for
CD34+-derived int-DC longevity. Conversely,
CD1a+ DCs express only RANK and are short-lived. However,
they can be rescued from cell death either by recombinant soluble
TRANCE or by CD34+-derived int-DCs.
CD34+-derived int-DCs mature in response to
lipopolysaccharide (LPS) plus CD40 ligand (L) and become
capable of CCL21/CCL19-mediated chemotaxis and naive T-cell activation.
Upon maturation, they lose TRANCE, making them, like CD1a+
DCs, dependent on exogenous TRANCE for survival. These findings provide
evidence that TRANCE and RANK play important roles in the homeostasis
of DCs.
(Blood. 2002;100:3646-3655)
